Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies wi

Results from this post-hoc analysis demonstrated improvements in bleeding outcomes in participants switching to rAHF-PEG and were consistent with the original trial results, supporting the feasibility of transitioning from the older- to newer-generation Takeda FVIII replacement therapies.

Authors

Institutions

Publication Details

Journal
Expert Review of Hematology
Published
2026-01-21
DOI
https://doi.org/10.1080/17474086.2026.2619440
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies wi

Caitlin Montcrieff, Jorge Caicedo, Leonard A. Valentino, Alicia Cerretani et al.
Expert Review of Hematology
Hemophilia Treatment and Research
article

Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies wi

Caitlin Montcrieff, Jorge Caicedo, Leonard A. Valentino, Alicia Cerretani, Jonathan Shtaynberger, Ian Robinson
article en

Abstract

Results from this post-hoc analysis demonstrated improvements in bleeding outcomes in participants switching to rAHF-PEG and were consistent with the original trial results, supporting the feasibility of transitioning from the older- to newer-generation Takeda FVIII replacement therapies.

Expert Review of Hematology
Rush University Medical Center (US), Takeda (United States) (US), Takeda (Japan) (JP)
Openalex Percentile: Top 84%
Hemophilia Treatment and Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies wi — Caitlin Montcrieff, Jorge Caicedo, et al. · Expert Review of Hematology (2026) | TGRS Research Map | TGRS